48 reports

Therapies and Diagnostics for Ovarian Cancer: Global Markets to 2022 Chapter ## Introduction Study Goals and Objectives Reasons for Doing This Study Scope of Report Methodology Geographic Breakdown Analyst’s Credentials Related BCC Research Reports Chapter ## Summary and Highlights Market Con

  • Cancer
  • Ovarian Cancer
  • Therapy
  • World
  • Market Size

Note: ##.

  • Ovarian Cancer
  • World
  • Forecast
  • bioMerieux S.A.
  • Cepheid

Rucaparib is a top-of-the-line pharmaceutical preparation for the repair polymerase of DNA polymerase-## (PARP-##) poly-ADP.

  • Ovarian Cancer
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

The auto exports exceeded over ## million each year.

  • Diagnostic Reagent
  • China
  • Demand
  • Market Size
  • Biosino Bio-Technology & Science Inc

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

The company produces and markets high-quality products and biologics in the areas of gastrointestinal disease, neurology, psychiatry, immunology, pain control, infectious disease, and oncology.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group

Jia No. ##, Hualan Ave., Xinxiang, Henan, ## P. R.

  • Diagnostic Reagent
  • China
  • Beijing BGI-GBI Biotech Co., Ltd
  • Biosino Bio-Technology & Science Inc
  • Livzon Group

APPENDIX ##: TABULATED DATA ##. ##.

  • Clinical Trial
  • Ovarian Cancer
  • United States
  • Forecast
  • Nektar Therapeutics
  • Dormant Projects, H1 2017
  • Dormant Products, H1 2018

The ODAC reviewed findings from one Phase III clinical study and one Phase II study.

  • Hospital
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Novartis AG
  • Dormant Products, H2 2017

The ODAC reviewed findings from one Phase III clinical study and one Phase II study.

  • Cancer
  • Oncology
  • Ovarian Cancer
  • Therapy
  • Novartis AG
  • Clinical Trial profile. 41 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Clinical Trial
  • Monoclonal Antibody
  • Ovarian Cancer
  • World
  • Product Initiative
  • PIPELINE BY CLOVIS ONCOLOGY INC, H2 2017
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H2 2017

PHIL., UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA DURING THE POSTER SESSION TITLED GASTROINTESTINAL (NON-COLORECTAL) CANCER".

  • Oncology
  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • AstraZeneca PLC
  • Clinical Trial profile. 136 Trial Title
  • Official Title

## ## ## Merck & Co Inc ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## Eli Lilly and Co ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Italian Sarcoma Group ## ## ##

  • Clinical Trial
  • Monoclonal Antibody
  • Ovarian Cancer
  • World
  • Product Initiative

The company' s product pipeline includes PI##K GDC-##; Cantrixil (TRX-E-##-##); Trilexium (TRXE-##-##).

  • Brain Cancer
  • Ovarian Cancer
  • Australia
  • United States
  • Novogen Limited
  • CLINICAL TRIAL PROFILE SNAPSHOTS

## ## ## ## ## ## Sanofi ## ## ## ## ## ## Regeneron Pharmaceuticals Inc ## ## ## ## ## ## MRC Biotech Pty Ltd (Inactive) ## ## ## ## ## ## Kazia Therapeutics Ltd ## ## ## ## ## ## HealthCare Global Enterprises Ltd ## ## ## ## ##

  • Ovarian Cancer
  • Therapy
  • World
  • Product Initiative
  • NeoPharm, Inc.
  • Clinical Trial profile. 369 Trial Title
  • Clinical Trial profile. 866 Trial Title

Peritoneal Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Peritoneal Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Peritoneal Cancer clinical trials scenario.This report provides top line data relating to the clinical trials on...

  • Cancer
  • Clinical Trial
  • Ovarian Cancer
  • World
  • Product Initiative

The company' s product pipeline includes PI##K GDC-##; Cantrixil (TRX-E-##-##); Trilexium (TRXE-##-##).

  • Brain Cancer
  • Ovarian Cancer
  • Australia
  • United States
  • Novogen Limited

The main treatment-emergent adverse events have been low grade gastrointestinal and central nervous system related events.

  • Cancer
  • Ovarian Cancer
  • United States
  • World
  • Product Initiative
  • PIPELINE BY CLOVIS ONCOLOGY INC, H1 2018
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H1 2018

GASTROINTESTINAL TEAES WERE IN LINE WITH HISTORIC IR-V DATA.

  • Oncology
  • Ovarian Cancer
  • Therapy
  • United States
  • AstraZeneca PLC
  • CLINICAL TRIAL PROFILE. 868 TRIAL TITLE
  • Clinical Trial profile. 2537 Trial Title

Peritoneal carcinomatosis is one of the most serious complications of gastrointestinal and gynecological malignancies.

  • Cancer
  • Chemotherapy
  • Clinical Trial
  • Ovarian Cancer
  • World
  • and hypoxia inducible factor 1alpha.

KCN-## acts by inhibiting hypoxia inducible factor ## alpha (HIF-## alpha) interaction.

  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cerulean

KCN-## acts by inhibiting hypoxia inducible factor ## alpha (HIF-## alpha) interaction.

  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative
  • Cerulean
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H1 2018
  • PIPELINE BY JIANGSU HENGRUI MEDICINE CO LTD, H1 2018

GASTROINTESTINAL TEAES WERE IN LINE WITH HISTORIC IR-V DATA.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • AstraZeneca PLC

Such endoscopic data reflect the ability of Brilacidin to help clear Gastrointestinal (GI) tract mucosa in patients suffering from UC.

  • Ovarian Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Cellceutix Corporation

The main treatment-emergent adverse events have been low grade gastrointestinal and central nervous system related events.

  • Monoclonal Antibody
  • Ovarian Cancer
  • Therapy
  • United States
  • Product Initiative

The interest at a rate of ##. ##% per annum is payable semiannually on May ## and November ## of each year.

  • Oncology
  • Ovarian Cancer
  • Therapy
  • United States
  • Clovis Oncology, Inc.
  • PIPELINE BY EISAI CO LTD, H1 2017
  • PIPELINE BY ILDONG PHARMACEUTICAL CO LTD, H1 2017

Gastrointestinal TEAEs were in line with historic IR-v data.

  • Cancer
  • Ovarian Cancer
  • United States
  • Product Initiative
  • AstraZeneca PLC
  • EPITHELIAL OVARIAN CANCER - PIPELINE BY EISAI CO., LTD., H1 2016
  • EPITHELIAL OVARIAN CANCER - PIPELINE BY PFIZER INC., H1 2016

The drug-related AEs were elevated liver enzymes and gastrointestinal AEs.

  • Monoclonal Antibody
  • Ovarian Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • METASTATIC OVARIAN CANCER - PIPELINE BY EISAI CO., LTD., H2 2016
  • METASTATIC OVARIAN CANCER - PIPELINE BY RICHTER GEDEON NYRT., H2 2016

The company' s franchise areas in research include neurology, oncology, vascular and immunological reaction, gastrointestinal disorders, and musculoskeletal diseases.

  • Ovarian Cancer
  • Therapy
  • United States
  • Company Operations
  • Product Initiative